Clovis Oncology (NASDAQ:CLVS) Now Covered by StockNews.com
Clovis Oncology (NASDAQ:CLVS) Now Covered by StockNews.com
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank grew its stake in Clovis Oncology by 17.9% in the first quarter. Swiss National Bank now owns 291,900 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 44,400 shares during the period. WINTON GROUP Ltd acquired a new position in Clovis Oncology in the first quarter valued at about $179,000. Bank of Montreal Can acquired a new position in Clovis Oncology in the first quarter valued at about $48,000. Panagora Asset Management Inc. grew its stake in Clovis Oncology by 3.2% in the first quarter. Panagora Asset Management Inc. now owns 574,225 shares of the biopharmaceutical company's stock valued at $1,160,000 after acquiring an additional 18,000 shares during the period. Finally, Vanguard Group Inc. grew its stake in Clovis Oncology by 22.1% in the first quarter. Vanguard Group Inc. now owns 12,348,898 shares of the biopharmaceutical company's stock valued at $24,945,000 after acquiring an additional 2,233,797 shares during the period. Institutional investors own 24.53% of the company's stock. StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research report sent to investors on Monday. The firm issued a hold rating on the biopharmaceutical company's stock.
證券新聞網開始對股票的報導 克洛維斯腫瘤科 (NASDAQ: CLVS — 獲得評級) 在星期一發送給投資者的研究報告中。該公司對該生物製藥公司的股票發出了持有評級。
Separately, JPMorgan Chase & Co. downgraded Clovis Oncology from a neutral rating to an underweight rating in a report on Wednesday, November 9th.
另外，摩根大通公司在 11 月 9 日（星期三）的一份報告中，將 Clovis 腫瘤醫學從中性評級降級為體重過輕。
Clovis Oncology Price Performance
克洛維斯腫瘤學價格表現
Clovis Oncology has a 52-week low of $0.08 and a 52-week high of $3.32. The business's fifty day moving average price is $0.56 and its two-hundred day moving average price is $1.15.
克洛維斯腫瘤學的 52 周低點為 0.08 美元，52 周高點為 3.32 美元。該企業的五十天移動平均價格為 0.56 美元，其 200 日移動平均價為 1.15 美元。
Institutional Investors Weigh In On Clovis Oncology
機構投資者權衡克洛維斯腫瘤學
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank grew its stake in Clovis Oncology by 17.9% in the first quarter. Swiss National Bank now owns 291,900 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 44,400 shares during the period. WINTON GROUP Ltd acquired a new position in Clovis Oncology in the first quarter valued at about $179,000. Bank of Montreal Can acquired a new position in Clovis Oncology in the first quarter valued at about $48,000. Panagora Asset Management Inc. grew its stake in Clovis Oncology by 3.2% in the first quarter. Panagora Asset Management Inc. now owns 574,225 shares of the biopharmaceutical company's stock valued at $1,160,000 after acquiring an additional 18,000 shares during the period. Finally, Vanguard Group Inc. grew its stake in Clovis Oncology by 22.1% in the first quarter. Vanguard Group Inc. now owns 12,348,898 shares of the biopharmaceutical company's stock valued at $24,945,000 after acquiring an additional 2,233,797 shares during the period. Institutional investors own 24.53% of the company's stock.
機構投資者和對沖基金最近增加或減少了他們在股票中的股份。瑞士國家銀行在第一季度將其在克洛維斯腫瘤學的股份增長了 17.9％。瑞士國家銀行現在擁有該生物製藥公司的 291,900 股股票，價值為 59 萬美元，在此期間額外收購了 44,400 股股份。運通泰集團有限公司於第一季度收購克洛維斯腫瘤科的新職位，價值約 179,000 美元。蒙特利爾銀行可以在第一季度收購了克洛維斯腫瘤學的新職位，價值約為 48,000 美元。Panagora 資產管理公司在第一季度增長了 3.2％ 在克洛維斯腫瘤學的股份。沛納高拉資產管理股份有限公司現在擁有該生物製藥公司股票的 574,225 股，價值 1,160,000 美元，在此期間另外收購 18,000 股股票。最後，先鋒集團公司在第一季度增長了 22.1％ 在克洛維斯腫瘤學的股份。領航集團股份有限公司現在擁有該生物製藥公司的 12,348,898 股股份，價值為 24,945,000 美元。機構投資者擁有公司股票的 24.53%。
About Clovis Oncology
關於克洛維斯腫瘤科
(Get Rating)
(取得評分)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology, Inc 是一家生物製藥公司，致力於在美國、歐洲和國際上收購、開發和商業化抗癌藥物。其商業產品包括 Rubraca（rucaparib）片劑，一種小分子聚 ADP-核糖聚合酶抑製劑，用於治療與晚期卵巢癌有害 BRCA 突變的患者的單一療法，並通過 FDA 批准的伴侶診斷為 Rubraca 選擇治療。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 獲取有關克洛維斯腫瘤學（CLVS）的研究報告的免費副本
- 您購買 Palantir 的決定可能只是時間問題
- 卡特彼勒和迪爾是否在 2023 年設置集會？
- 馬倫汽車獲取一個顛簸作為 I-GO 到達歐洲
- 在 2023 年，陽光會在這 3 個大型股太陽能股上閃耀嗎？
- 清醒汽車面臨的現實可能會影響看漲的感知
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收克洛維斯腫瘤日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Clovis 腫瘤學和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
